Elisabeth Ersvær
0000-0002-9617-9329
65 papers found
Refreshing results…
Primary Human Aml Cells Can Express Calreticulin on the Cell Surface and Release Heat Shock Protein 70 (Hsp70) and Hsp90 During Apoptosis
Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience
Primary Human Acute Myelogenous Leukemia Cells Release Heat Shock Protein (Hsp) 70 and Hsp90 During Apoptosis
The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells
The protein kinase C agonist PEP005 increases NF-κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells
Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators
Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors
Anticancer Immunotherapy in Combination with Proapoptotic Therapy
Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators
In Vitro Induction of a Dendritic Cell Phenotype in Primary Human Acute Myelogenous Leukemia (AML) Blasts Alters the Chemokine Release Profile and Increases the Levels of T Cell Chemotactic CCL17 and CCL22
Chemokine Receptor Expression by Circulating T Cells Derived From Acute Leukemia Patients With Severe Chemotherapy-Induced Cytopenia Express a Wide Range of Chemokine Receptors
Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients
Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
The protein kinase C activator PEP005 increases the chemokine release in native acute myelogenous leukemia (AML) blasts
In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts: The chemokine release profile of the AML dendritic cells depends on the experimental protocol
Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90
Missing publications? Search for publications with a matching author name.